A2DaZ Tuesday, 10/23/18 04:40:29 PM Re: Genomer post# 35608 0 Post # of 35640 It would no doubt, but the the debt with this company far exceeds any record revs or cash flow on the books at this juncture. It would take some miracle for Cashman to grab more business and rake in more revenues to offset or even pay off the debt. Like Grantastic noted it’s a “running” deficit more than anything else. It’s going to take years for this pos scumbag to get this company out of the hole. Obviously he hasn’t cared about this issue nor has he updated investors or shareholders on what his “plans” are moving forward. As you know dilution or debt are the biggest downfall in OTC companies. Perhaps how he is running the company from a “private” operation might be putting food on his and his employees table, but the public aspect has been “ignored” for a long time now and continuously screwing over investors and shareholders. The last “run” was a p&d on false promises. Most will agree here.